The investment objective is to deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes. The Company will target an IRR per share across its investment portfolio of 15% p.a. over the long term. Over time, it is intended that the Company should invest the significant majority of its assets in Life Science Investments.
Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science
https://www.londonstockexchange.com/stock/SYNC/syncona-limited/company-page